A73 Rec'd PCT/PTO 15 MAR

Atty Docket No. 104916 (CS0439/US/2) Express Mail Label No. EV 785819441 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Jianxin Bao

1647

Serial No .:

10/550,673

Filing Date:

September 26, 2005

Examiner:

For:

NEUREGULIN PROTEIN

Conf. No.

Art Unit

REGULATION OF SYNAPTIC

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, Applicant submits the attached PTO/SB/08A and B forms for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein. Copies of Reference Nos. 30-113 are enclosed.

In addition, this Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(b) in that Applicant believes that it is being filed prior to the mailing date

CERTIFICATE OF MAILING

I hereby certify that, on the date shown below, this correspondence is being

deposited with the United States Postal Service in an envelope addressed to Mail Stop: PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MAILING

37 C.F.R. §1.8

as first class mail.

37 C.F.R. §1.10

as "Express Mail Post Office to Addressee" EXPRESS MAIL NO. EV 785819441 US

FACSIMILE TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

M. Sue Clements Name of Depositor

Signature

PATENT

Atty Docket No. 104916 (CS0439/US/2) Express Mail Label No. EV 785819441 US

of the first Office action on the merits. Accordingly, neither a statement nor fee under 37 C.F.R. §1.97(c) or (d) is required. However, if an Office action was issued prior to the date of mailing of this Information Disclosure Statement, the Commissioner is hereby authorized to charge any required fees regarding this Information Disclosure Statement to Deposit Account 50-1662.

Respectfully submitted,

POLSINEILLI SHALTON WELTE SUELTHAUS PC

Date: March 15, 2006

Kathryn J. Doty, Reg No. 40,593 100 South Fourth Street, Suite 1100

St. Louis, Missouri 63102

Tel: (314) 552-6850 Fax: (314) 231-1776 Attorney for Applicant

047563 / 104916 KJDOT 311903

CERTIFICATE OF M	IAILING BY "EXPRESS MAI	Matte	er No.	
Applicant(s): Jianx	in Bao	104916 (CS	0439/US/2)	
Serial No.	Filing Date or 371 Date	Examiner	Group Art Unit	Confirmation No.
10/550,673	September 26, 2005	TBA	1647	1449

Invention: NEUREGULIN PROTEIN REGULATION OF SYNAPTIC PROTEINS

I hereby certify that: an Information Disclosure Statement Letter to the U.S. Patent and Trademark Office (2 pages); Forms PTO/SB/08A and B Information Disclosure Statement by Applicant (6 pages); One (1) copy of Reference Nos. 30-113; Certificate of Mailing by Express Mail (1 page); authorization to charge any fees which may be required or credit any overpayments to Deposit Account No. 50-1662; and a stamped, pre-addressed postcard are being mailed by U.S. Postal Service Express Mail to Addressee: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 15th day of March, 2006.

M. Sue Clements

(Typed or Printed Name of Person Mailing Correspondence)

7. Ju Ulmins
(Signature of Person Mailing Correspondence)

EV 785819441 US

("Express Mail" Mailing Label Number)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	estitute for form 1449/PTO			Complete if Known		
Substitu	te for form 1449/P	10		Application Number	10/550,673	
NFORMATION DISCLOSURE				Filing Date	September 26, 2005	
	EMENT BY A			First Named Inventor	Jianxin Bao	
_	as many sheet			Art Unit	1647	
,000	ac many onect	. u	,	Examiner Name	To be assigned	
Sheet	1	of	6	Attorney Docket Number	104916 (CS0439-01/US/2)	

			U.S PATENT DO	CUMENTS	
Examin er Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (IF KNOWA)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appeal
	1	US 5,364,759	11-15-1994	Caskey et al.	
	2	US 5,364,934	11-15-1994	Drayna et al.	
	3	US 5,534,416	07-09-1996	Millard et al.	
	4	US 5,614,364	03-25-1997	Tuggle et al.	
	5	US 5,627,643	05-06-1997	Birnbaum et al.	
	6	US 5,738,996	04-14-1998	Hodges et al.	
	7	US 5,786,155	07-28-1998	Weinshank et al.	
	8	US 5,804,436	09-08-1998	Okun et al.	
	9	US 5,807,683	09-15-1998	Brenner	
	10	US 5,856,104	01-05-1999	Chee et al.	
	11	US 5,942,443	08-24-1999	Parce et al.	
	12	US 5,976,814	11-02-1999	Bard et al.	
	13	US 5,990,128	11-23-1999	Gluchowski et al.	
	14	US 6,001,231	12-14-1999	Kopf-Sill	
	15	US 6,007,988	12-28-1999	Choo et al.	
	16	US 6,046,056	04-04-2000	Parce et al.	
	17	US 6,074,831	06-13-2000	Yakhini et al.	
	18	US 6,132,685	10-17-2000	Kercso et al.	
	19	US 6,132,970	10-17-2000	Stemmer	
	20	US 6,149,787	11-21-2000	Chow et al.	
	21	US 6,171,781 B1	01-09-2001	Crabtree et al.	
	22	US 6,172,197 B1	01-09-2001	McCafferty et al.	
	23	US 6,416,959 B1	07-09-2002	Giuliano et al.	
	24	US 6,518,065 B1	02-11-2003	Stemmer	
	25	US 6,529,835 B1	03-04-2003	Wada et al.	
	26	US 6,933,122 B1	08-23-2005	Role et al.	
	27	US 2001/0041347 A1	11-15-2001	Sammak et al.	
	28	US 2002/0042366 A1	04-11-2002	Thompson et al.	
	29	US 2002/0098588 A1	07-25-2002	Sammak et al.	

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformance and no considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must proceed the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. patent and Trademark Office, PO Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paper Work Reduction Act of 1995, no person are required to respond to a collection of information unless it contains a valid OMB control number.

0 1 - 11 - 1	O halibda fa fa wa 4440/DTO			Complete if Known	
Substitute for form 1449/PTO				Application Number	10/550,673
INFORMATION DISCLOSURE STATEMENT BY APPLICATION			SIIDE	Filing Date	September 26, 2005
				First Named Inventor	Jianxin Bao
_	as many sheets		_	Art Unit	1647
(coo ac many enests as needed by		Examiner Name	To be assigned		
Sheet	2	of	6	Attorney Docket Number	104916 (CS0439-01/US/2)

		FORE	IGN PATENT [OCUMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ^{5(#} known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
	30	WO 91/10734	07-25-1991	HSC Research Development Corp.		
	31	WO 02/14475 A2	02-21-2002	The Trustees of Columbia University in the City of New York		
	32	WO 03/040333 A2	05-15-2003	Albert Einstein College of Medicine of Yeshiva University		

		NON-PATENT LITERATURE ARTICLES	
Examiner Initials*	Cite No. ¹	Include name of the authority (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	33	AARTS, M., et al., "Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions", <i>Sci</i> (2002) pp. 846-50, Vol. 298.	
	34 ,	ALT, F.W., et al., "Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells", <i>J. Biol. Chem.</i> (1978) p. 1357-70, Vol. 253, No. 5.	
	35	ALTSCHUL, S.F., et al., "Basic local alignment search tool", <i>J. Mol. Biol.</i> (1990) pp. 403-10, Vol. 215.	
	36 -	AMANN, E., et al., "ATG vectors' for regulated high-level expression of cloned genes in Escherichia coli", <i>Gene</i> (1985), p. 183-90, Vol. 40.	
	37	BAO, J., et al., "CNIP: A Novel Interactor Protein Specific for the Cytoplasmic Domain of CRD Neuregulin", Soc. for Neurosci. (1997), p. 562.1, Vol. 23.	
	38 .	BAO, J., et al., "Back signaling by the Nrg-1 intracellular domain", <i>J. Cell Biol.</i> (2003) pp 1133-41, Vol. 161, No. 6.	
	39	BAO, J., et al., "Activity-dependent transcription regulation of PSD- ₉₅ by neureglin-1 and Eos", <i>Nature Neuro</i> . (2004) pp. 1250-8, Vol. 7, No. 11.	
	40	BERGER, S.A., et al., "Characterization of a Retrovirus Shuttle Vector Capable of Either Proviral Integration or Extrachromosomal Replication in Mouse Cells", <i>Mol. Cell. Bio.</i> (1985) pp. 305-12, Vol. 5, No. 2.	
	41	BOLTON, E.T., et al., "A General Method for the Isolation of RNA Complementary to DNA", Proc. Natl. Acad. Sci. USA (1962) p. 1390-7, Vol. 48.	
	42 /	BONNER, T.I., "Reduction in the rate of DNA reassociation by sequence divergence", <i>J. Mol. Biol.</i> (1973) p. 123-35, Vol. 81.	
	43	BRASH, D.E., et al., "Strontium Phosphate Transfection of Human Cells in Primary Culture: Stable Expression of the Simian Virus 40 Large-T-Antigen Gene in Primary Human Bronchial Epithelial Cells", <i>Mol. Cell Biol.</i> (1987) p. 2031-4, Vol. 7, No. 5.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in

conformance and no considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional).

'Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. patent and Trademark Office, PO Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Under the Paper Work Reduction Act of 1995, no person are required to respond to a collection of information unless it contains a valid OMB control number.

	2.1.11.1.1			Complete if Known		
Substitute for form 1449/PTO				Application Number	10/550,673	
INIEGE	MATION DIS	כו כ	SIIDE	Filing Date	September 26, 2005	
1	INFORMATION DISCLOSURE STATEMENT BY APPLICATION			First Named Inventor	Jianxin Bao	
_	as many sheets			Art Unit	1647	
,,,,,	(obc as many enects as necessary)		Examiner Name	To be assigned		
Sheet	3	of	6	Attorney Docket Number	104916 (CS0439-01/US/2)	

44	BUONANNO, A., et al., "Neuregulin and ErbB receptor signaling pathways in the nervous	
	system", Curr. Opin. Neurobiol. (2001) pp. 287-96, Vol. 11.	
45	BURGESS, T.L., et al., "Biosynthetic Processing of <i>neu</i> Differentiation Factor", <i>J. Biol. Chem.</i>	
	(1995) pp. 19188-96, Vol. 270, No. 32.	_
46	BURKE, D.T., et al., "Cloning of large segments of exogenous DNA into yeast by means of artificial chromosome vectors", <i>Sci</i> (1987) pp. 806-12, Vol. 236.	
47	CARRAWAY, K.L. III, et al., "Neuregulin and their receptors", Curr. Opin. Neurobiol (1995)	_
	pp. 606-12, Vol. 5.	
48	CHAMBERLAIN, J.S., et al., "Deletion screening of the Duchenne muscular dystrophy locus	
	via multiplex DNA amplification", Nucl. Acids Res. (1988) pp. 11141-55, Vol. 16, No. 23.	
49	CHANG, LJ., et al., "Inhibition of Rous Sarcoma Virus Replication by Antisense RNA", J.	
	Virol (1987) pp. 921-4, Vol. 61, No. 3.	
50	CHURCH, G.M., et al., "Genomic sequencing (DNA meythylation/UV/filter hybridization/	
	immunoglobulin genes)", Proc. Natl. Acad. Sci. USA (1984) pp. 1991-5, Vol. 81.	
51	COHEN-CORY, S., et al., "The Developing Synapse: Construction and Modulation of	
	Synaptic Structures and Circuits", Sci (2002) pp. 770-6, Vol. 298.	
52	COTTON, R.G.H., et al., "Reactivity of cytosine and thymine in single-base-pair mismatches	
1 .	with hydroxylamine and osmium tetroxide and its application to the study of mutations", <i>Proc.</i>	
	Natl. Acad. Sci. USA (1988) pp. 4397-4401, Vol. 85.	
53	EL-HUSSEINI, A.E., et al., "PDS-95 involvement in maturation of excitatory synapses", Sci	
	(2000) pp. 1364-8, Vol. 290.	
54	FARINAS, J., et al., "Receptor mediated targeting of fluroescent probes in living cells", J Biol	
	Chem (1999) pp. 7603-6, Vol. 274, No. 12.	
55	FELGNER, P.L., et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection	
	procedure", <i>Proc. Natl. Acad. Sci. USA</i> (1987) p. 7413-7, Vol. 84.	
56	FLAVELL, R.A., et al., "Analysis of the beta-delta-globin gene loci in normal and Hb Lepore	
'		
	Vol. 15.	
57	GASSER, C.S., et al., "Genetically Engineering Plants for Crop Improvement", Sci (1989)	
	pp. 1293-9, Vol. 244, No. 4910.	
58	GEBEYEHU, G., et al., "Novel biotinylated nucleotide – analogs for labeling and colorimetric	
	detection of DNA", Nucleic Acids Res. (1987) pp. 4513-34, Vol. 15, No. 11.	_
59	GEORGOPOULOS, K., "Haematopoietic cell-fate decisions, chromatin regulation and ikaros",	
	Nat. Rev. Immunol. (2002) pp. 162-74, Vol. 2.	
60	GLUZMAN, Y., "SV40-transformed simian cells support the replication of early SV40 mutants",	
	Cell (1981) pp. 175-82, Vol. 23, No. 1.	
61	GORMAN, C.M., et al., "The Rous sarcoma virus long terminal repeat is a strong promoter	
-	when introduced into a variety of eukaryotic cells by DNA-mediated transfection", <i>Proc. Natl.</i>	
	Acad. Sci. USA (1982) pp. 6777-81, Vol. 79.	
62	GRAHAM, F.L., "Transformation of rat cells by DNA of human adenovirus 5", Virology (1973)	
	pp. 536-9, Vol. 54.	_

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in

conformance and no considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. patent and Trademark Office, PO Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Under the Paper Work Reduction Act of 1995, no person are required to respond to a collection of information unless it contains a valid OMB control number.

	0.1.471.4.5.5			Complete if Known		
Substitute for form 1449/PTO				Application Number	10/550,673	
INFORMATION DISCLOSURE				Filing Date	September 26, 2005	
1 -	STATEMENT BY APPLICATION			First Named Inventor	Jianxin Bao	
	(Use as many sheets as necessary)		Art Unit	1647		
(000 00 11101)		Examiner Name	To be assigned			
Sheet	4	of	6	Attorney Docket Number	104916 (CS0439-01/US/2)	

63	GRAY, et al., "Open reading frame cloning: Identification, cloning, and expression of open reading fram DNA", <i>Proc. Natl. Acad. Sci. USA</i> (1982) pp. 6598-6602, Vol. 79.	
64	GRIMM, S., et al., "Neu Differentiation Factor (NDF), a Dominant Oncogene, Causes Apoptosis In Vitro and In Vivo", <i>J. Exp. Med.</i> (1998) pp. 1535-9, Vol. 188, No. 8.	
65	HAJ-AHMAD, Y., et al., "Development of a Helper-Independent Human Advenovirus Vector and Its Use in the Transfer of the Herpes Simplex Virus Thymidine Kinase Gene", J. Virol. (1986) pp. 267-74, Vol. 57, No. 1.	
66 .	HONMA, Y., et al., "Eos: a novel member of the Ikaros gene family expressed predominantly in the developing nervous system", FEBS Letters 447 (1999) pp. 76-80, FEBS 21733.	
67	IZANT, J.G., et al., "Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA", <i>Sci</i> (1985) pp. 345-52, Vol. 229.	
68	KARLIN, S., et al., "Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes", <i>Proc. Natl. Acad. Sci. USA</i> (1990) pp. 2264-8, Vol. 87.	
69	KASID, U., et al., "Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma", <i>Sci</i> (1989) pp. 1354-6, Vol. 243.	
70	KHOKHA, R., et al., "Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells", <i>Sci</i> (1989) pp. 947-50, Vol. 243.	
71	KLEIN, et al., "High-velocity microprojectiles for delivering nucleic acids into living cells", <i>Nat.</i> (1987) pp. 70-3, Vol. 327.	
72	LANDEGREN, U., et al., "A Ligase-Mediated Gene Detection Technique", <i>Sci</i> (1988) pp. 1077-80, Vol. 241.	
73	LANGER, P.R., et al., "Enzymatic synthesis of biotin-labeled polynucleotides: Novel nucleic and affinity probes", <i>Proc. Natl. Acad. Sci. USA</i> (1981) pp. 6633-7, Vol. 78, No. 11.	
74	LEE, et al., "Glucocorticoids regulate expression of dihydrofolate reductase cDNA in mouse mammary tumour virus chimaeric plasmids", <i>Nature</i> (1981) pp. 228-32, Vol. 294.	
75	LEE, et al., "Presenilin-dependent gamma-Secretase-like Intramembrane Cleavage of ErbB4", J. Biol. Chem. (2002) pp. 6318-23, Vol. 277, No. 8.	
76	LIU, Q., et al., "Identification of active site residues in the "GyrA" half of yeast DNA Topoisomerase II", J. Biol. Chem. (1998) pp. 205252-20260, Vol. 273, No. 32.	
77	MANN, D.A., et al., "Endocytosis and targeting of exogenous HIV-1 Tat protein", <i>EMBO J.</i> (1991) p. 1733-9, Vol. 10, No. 7.	
78	MAO, J., et al., "Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway", <i>Mol Cell</i> (2001) pp. 801-9, Vol. 7.	
79	MARGOLSKEE, R.F., et al., "Epstein-Barr Virus Shuttle Vector for Stable Episomal Replication of cDNA Expression Libraries in Human Cells", <i>Mol. Cell. Biol.</i> (1988) pp. 2837-47, Vol. 8, No. 7.	
80 .	McCUTCHAN, J.H., et al., "Enchancement of the infectivity of simian virus 40 deoxyribonucleic acid with diethylaminoethyl-dextran", <i>J. Natl. Cancer Inst.</i> (1968) pp. 351-7, Vol. 41, No. 2.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in

conformance and no considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).
Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. patent and Trademark Office, PO Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Under the Paper Work Reduction Act of 1995, no person are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449/PTO			Complete if Known		
Substitut	e for form 1449/P1	O		Application Number	10/550,673	
INFORMATION DISCLOSURE				Filing Date	September 26, 2005	
	STATEMENT BY APPLICATION			First Named Inventor	Jianxin Bao	
	as many sheets			Art Unit	1647	
(ood do many ondere de noodsally,		Examiner Name	To be assigned			
Sheet	5	of	6	Attorney Docket Number	104916 (CS0439-01/US/2)	

81	McLAUGHLIN, S.K., et al., "Adeno-Associated Virus General Transduction Vectors: Analysis of Proviral Structures", <i>J. Virol.</i> (1988) pp. 1963-73, Vol. 62, No. 6.
82	MOSS, B., et al., Vaccinia Virus Expression Vectors", Annu. Rev. Immunol. (1987) pp. 305-24,
	Vol. 5.
83	MUELLER, C., et al., "Mapping of Early SV40-Specific Functions by Microinjection of Different
	Early Viral DNA Fragments", <i>Cell</i> (1978) p. 579, Vol. 15.
84	MULLIGAN, R.C., et al., "Factors Governing the Expression of a Bacterial Gene in
	Mammalian Cells", Mol and Cell Biol (1981) pp. 449-59, Vol. 1, No. 5.
85	MYERS, R.M., et al., "Recent advances in the development of methods for detecting single-
	base substitutions associated with human genetic diseases." Cold Spring Harb Symp Quant
	Biol. (1986) pp. 275-84, Vol. LI.
86	MYERS, R.M., et al., "Detection of single base substitutions by ribonuclease cleavage at
	mismatches in RNA:DNA duplexes", <i>Sci</i> (1985) pp. 1242-6, Vol. 230.
87	NAGAMINE, C.M., et al., "A PCR artifact: generation of heteroduplexes", Am J Hum Genet.
1	(1989) pp. 337-9, Vol. 45, No. 2.
88	NEUMANN, E., et al., "Gene transfer into mouse lyoma cells by electroporation in high electric
	fields", <i>EMBO J.</i> (1982) pp. 841-5, Vol. 1, No. 7.
89	NEILSEN, P.E., et al., "Sequence-selective recognition of DNA by strand displacement with a
	thymine-substituted polyamide", Sci (1991) pp. 1497-1500, Vol. 254.
90	OHLEMILLER, K.D., et al., "Vulnerability to noise-induced hearing loss in 'middle-aged' and
	young adult mice: a dose-response approach in CBA, C57BL, and BALB inbred strains", Hear.
	Res. (2000) pp. 239-47, Vol. 149.
91	PERDOMO, J., et al., "Eos and Pegasus, Two Members of the Ikaros Family of Proteins with
	Distinct DNA Binding Activities", J. Biol. Chem. (2000) pp. 38347-54, Vol. 275, No. 49.
92	. PURSEL, V.G., et al., "Genetic engineering of livestock", Sci (1989) pp. 1281-8, Vol. 244.
93	RASMUSSEN, C.D., et al., "Methods for analyzing bovine papilloma virus-based calmodulin
	expression vectors", Methods Enzymol. (1987) pp. 642-54, Vol. 139.
94	RUTHER, U., et al., "Easy identification of cDNA clones", EMBO J. (1983) pp. 1791-4, Vol. 2,
	No. 10.
95	SAIKI, R.K., et al., "Genetic analysis of amplified DNA with immobilized sequence-specific
	oligonucleotide probes", Proc. Natl. Acad. Sci. USA (1989) pp. 6230-4, Vol. 86.
96	, SARVER, N., et al., "Bovine Papilloma Virus Deoxyribonucleic Acid: a Novel Eucaryotic
	Cloning Vector", Mol. Cell. Bio. (1981) pp. 486-96, Vol. 1, No. 6.
97	SCHAFFNER, W., "Direct transfer of cloned genes from bacteria to mammalian cells", Proc.
	Natl. Acad. Sci. USA (1980) pp. 2163-7, Vol. 77, No. 4.
98	. SHIMATAKE, H., et al., "Purified lambda regulatory protein cll positively activates promoters
	for lysogenic development", Nature (1981) pp. 128-32, Vol. 292.
99	SOUTHERN, E.M., "Detection of specific sequences among DNA fragments separated by gel

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in

conformance and no considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).
Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. patent and Trademark Office, PO Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paper Work Reduction Act of 1995, no person are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/550,673
INFORMATION DISCLOSURE STATEMENT BY APPLICATION			SURE	Filing Date	September 26, 2005
				First Named Inventor	Jianxin Bao
(Use as many sheets as necessary)				Art Unit	1647
(coo as many shoots as necessary)			,,,	Examiner Name	To be assigned
Sheet	6	of	6	Attorney Docket Number	104916 (CS0439-01/US/2)

100	SOUTHERN, P.J., et al., "Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter", <i>J. Mol. Appl. Genet.</i> (1982) pp. 327-41, Vol. 1, No. 4.
101	SPAETE, R.R., et al., "The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector", <i>Cell</i> (1982) pp. 295-304, Vol. 30.
102	STANLEY, K.K., et al., "Construction of a new family of high efficiency bacterial expression vectors: identification of cDNA clones coding for human liver proteins", <i>EMBO J.</i> (1984) pp. 1429-34, Vol. 3, No. 6.
103	STATHAKIS, D.G., et al., "Genomic Organization of Human <i>DLG4</i> , the Gene Encoding Postsynaptic Density 95", <i>J. Neurochem</i> (1999) pp. 2250-65, Vol. 73, No. 6.
104	STOFLET, E.S., et al., "Genomic amplification with transcript sequencing", <i>Sci</i> (1988) pp. 491-4, Vol. 239.
105	STUDIER, F.W., et al., "Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes", <i>J. Mol. Biol.</i> (1986) pp. 113-30, Vol. 189.
106	SUGDEN, B., et al., "A Vector That Replicates as a Plasmid and Can Be Efficiently Selected in B-Lymphoblasts Transformed by Epstein-Barr Virus", <i>Mol. Cell. Biol.</i> (1985) pp. 410-13, Vol. 5, No.2.
107	TIMBERLAKE, W.E., et al., "Genetic engineering of filamentous fungi", <i>Sci</i> (1989) pp. 1313-7, Vol. 244.
108	von RUDEN, T., et al., "Inhibition of Human T-Cell Leukemia Virus Type I Replication in Primary Human T Cells That Express Antisense RNA:, <i>J. Virol.</i> (1989) pp. 677-82, Vol. 63, No. 2.
109	WANG, J.Y., et al., "Transmembrane Neuregulins Interact with LIM Kinase 1, a Cytoplasmic Protein Kinase Implicated in Development of Visuospatial Cognition", <i>J. Bio. Chem.</i> (1998) pp. 20525-34, Vol. 273, No. 32.
110	WANG, J.Y., et al., "The N-terminal Region of Neuregulin Isoforms Determines the Accumulation of Cell Surface and Released Neuregulin Ectodomain ", <i>J. Bio. Chem.</i> (2001) pp. 2841-51, Vol. 276, No. 4
111	WRISCHNIK, L.A., et al., "Length mutations in human mitochondrial DNA: direct sequencing of enzymatically amplified DNA", <i>Nucl. Acids Res.</i> (1987) pp. 529-42, Vol. 15, No. 2.
112	YANG, F., et al., "Highly efficient green fluorescent protein based kinase substrates", Analyitical Biochem. (1999) pp. 167-73, Vol. 266.
113	International Search Report for PCT/US04/09499, dated 21 November 2005, 3 pgs. (104917).

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in

conformance and no considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional).

'Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. patent and Trademark Office, PO Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.